Dr. Youngblood on the Process of T-Cell Differentiation in Pediatric Solid Tumors

Benjamin A. Youngblood, PhD
Published: Thursday, Aug 23, 2018



Benjamin A. Youngblood, PhD, assistant member, Department of Immunology, St. Jude Children’s Research Hospital, discusses the process of T-cell differentiation in pediatric solid tumors.

Youngblood, an epigenetic specialist, says he works regularly with clinicians to look at donated solid tumor samples. The biggest aspect of analysis is to figure out why the T cells aren’t functioning properly. The microenvironment of the cells is also important, as well as determining if the T cells are interacting outside the tumor itself. This all impacts the cells’ endogenous response.

Youngblood says he is working with Stephen Gottschalk, MD, at St. Jude Children’s Research Hospital to characterize the differentiation in chimeric antigen receptor (CAR) T cells. This process involves looking at functional cell responses and defining these at an epigenetic level. With this information, Youngblood says, researchers can decide what the CAR T cells should look like compared with how their samples look. This could eventually be applied to targeted therapy in pediatric solid tumors.


Benjamin A. Youngblood, PhD, assistant member, Department of Immunology, St. Jude Children’s Research Hospital, discusses the process of T-cell differentiation in pediatric solid tumors.

Youngblood, an epigenetic specialist, says he works regularly with clinicians to look at donated solid tumor samples. The biggest aspect of analysis is to figure out why the T cells aren’t functioning properly. The microenvironment of the cells is also important, as well as determining if the T cells are interacting outside the tumor itself. This all impacts the cells’ endogenous response.

Youngblood says he is working with Stephen Gottschalk, MD, at St. Jude Children’s Research Hospital to characterize the differentiation in chimeric antigen receptor (CAR) T cells. This process involves looking at functional cell responses and defining these at an epigenetic level. With this information, Youngblood says, researchers can decide what the CAR T cells should look like compared with how their samples look. This could eventually be applied to targeted therapy in pediatric solid tumors.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x